ABOUT
Veritas In Silico is unveiling the mysteries of RNA and harnessing the potential of messenger RNA (mRNA) as a drug target. Powered by our proprietary in silico technology, we have established an entirely new system for drug discovery that focuses on finding drugs against structural motifs on mRNA.
The discovery of drugs that target mRNA is a promising direction for drug development and a new paradigm for the pharmaceutical industry. It has the potential for application to any disease, including those for which conventional protein-targeted discovery has not yielded effective treatments.
Veritas In Silico’s mission is to build a society where every patient, especially those with diseases that currently have no satisfactory treatment, can look forward to a brighter future through the realization of mRNA-targeted drugs.
With our ibVIS platform that combines informatics (i) and experimental biology (b), we at Veritas In Silico (VIS) will bring to fruition mRNA-targeted drugs.
The most distinctive feature of the ibVIS platform is its ability to maximize the existing drug discovery infrastructure — the technologies, experience, and chemical libraries — of our partner companies. We believe that the ibVIS platform will help to uncover the many hidden possibilities of mRNA as a drug target.
Armed with our platform and as pathfinders, we will guide companies willing to embark upon this new frontier of mRNA-targeted drug discovery.
The story behind our name, Veritas In Silico
Inspired by the Latin saying in vino veritas or “in wine there is truth,” Veritas In Silico means that the truth will be revealed through computer-powered biological research.
The company name conveys our strengths, approaching the truth through deduction by using in silico technologies and verifying such truths using experimental biology approaches that enable the discovery of mRNA-targeted drugs.
Company Profile
| Name | Veritas In Silico Inc. |
|---|---|
| Main Office | 1-11-1 Nishigotanda, Shinagawa-ku, Tokyo 141-0031 Japan |
| Research Facilities | Basic Research Facility Kanagawa, Japan Applied Research Facility Niigata, Japan |
| Established | November 17, 2016 |
| Employees | 14 |
| Business Description | Platform business for the discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs |
Basic Research Facility in Kanagawa
History
November 2016
Veritas In Silico founded
The company was founded to discover mRNA-targeted small molecule and antisense oligonucleotide (ASO) drugs based on the in silico technology of RNA structural analysis, with its head office located in Shibuya, Tokyo.
May–August 2017
Capital raised through Series A financing
The company raised capital in Series A financing from Mitsubishi Gas Chemical Company, Inc. (MGC) and three venture capital firms and its business has started in earnest.
Research focuses: ASO and sgASO drug discovery
The company initially focused on discovering ASOs and small guide antisense oligonucleotides (sgASOs), which have lengths less than half of the regular ASOs.
July 2017
Research facility opened at NUPALS
The company opened its Applied Research Division in Niigata, at the Niigata University of Pharmacology and Applied Health Sciences (NUPALS) where Professor Masayuki Nashimoto, a leading scientist in the sgASO field, belongs.
Launch of the mRNA-targeted small molecule drug discovery
The company made a strategic decision to quickly add research capacity for mRNA-targeted small molecule drug discovery, seeing as several U.S. companies pursuing RNA-targeted small molecule drug discovery had established.
October 2017
Head office transferred
The company transferred its head office to its current location in Shinagawa, Tokyo.
March 2018
First joint research for mRNA-targeted small molecule drug discovery
The company started the first joint research with one of the domestic pharmaceutical companies to discover mRNA-targeted small molecule drugs.
April 2018
Research facility opened at KBIC
The company opened its Basic Research Division for mRNA-targeted small molecule drug discovery in Shin-Kawasaki, at the Kawasaki Business Incubation Center (KBIC).
March-April 2019
Capital raised through Series B financing
The company raised capital in Series B financing from the existing shareholders and three additional venture capital firms, which led to the decision to focus on mRNA-targeted small molecule drug discovery officially.
October 2020
Acquisition of a business model patent
The company obtained a business model patent for RNA-targeted small molecule drug discovery (Japan).
December 2021
Capital raised through Series C financing
The company decided to expand the drug discovery platform business for mRNA-targeted small molecule drugs by developing or introducing new technologies.
May 2023
Business cooperation with CRO
The company entered an MOU with Oncodesign Services, a well-known CRO in France, to meet the wide-ranging needs of pharmaceutical companies seeking to develop mRNA-targeted small molecule drugs.
February 2024
Listed on the Growth market of the Tokyo Stock Exchange
As of February 2024
Joint Drug Discovery Research Underway with 4 partners
The company is now conducting joint drug discovery research with Toray Industries, Inc., Shionogi Inc., RaQualia Pharma Inc. and Takeda Pharmaceutical Company Limited. to create mRNA-targeted small molecule drugs.
